How much funding has Telomir Pharmaceuticals raised?

Telomir Pharmaceuticals has disclosed $2M raised across 2 rounds.

Where is Telomir Pharmaceuticals headquartered?

Telomir Pharmaceuticals is headquartered in Tampa, US.

Telomir Pharmaceuticals

NASDAQ: TELO

Tampa, US · Founded 2021 · Florida corporation · 1 known investors

Find your way into Telomir Pharmaceuticals

Paths you didn't know you had: your email and LinkedIn already hold routes to the Telomir Pharmaceuticals team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Telomir Pharma develops Telomir-Zn, a first-in-class oral therapy that modulates intracellular metal homeostasis to affect iron-dependent epigenetic machinery and reactivate tumor-suppressor genes silenced in cancer. Its lead program targets advanced and metastatic triple-negative breast cancer (TNBC), with an FDA-cleared IND for the TELO-001 Phase 1/2 clinical trial.

Biotech Healthtech

Founders & leadership

James McNultyTreasurer, Chief Financial Officer and Secretary

Chris ChapmanPresident, Chief Executive Officer and Chairman

Erez AminovChairman and Chief Executive Officer

Andriy MushakChief Financial Officer, Treasurer and Secretary

Board

Tuck TalhiaBoard director

Craig EagleBoard director

David VorhoffBoard director

Hugh McCollBoard director

Jude UzonwanneBoard director

Investors · 1

Also in the syndicate · 1

The Starwood Trust

Funding

SEC filings, press & company announcements

$2M disclosed across 2 rounds · 2023–2024

$1MraisedDec 2024 · 3 sources
The Starwood Trust
Source ↗

▶$1MraisedApr 2023 · 10 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Tuck TalhiaDirector
Craig EagleDirector
David VorhoffDirector
James McNultyExecutive Officer
Chris ChapmanExecutive Officer, Director
Hugh McCollDirector
Jude UzonwanneDirector

Offering amount: $1M
Amount sold: $1M
Sales commissions: $90K
Placement agents: Skyway Capital Markets, LLC
First sale: Mar 2023
Incorporated: Corporation, Florida, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - BioSpacebiospace.com · Dec 2024

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Pricefinance.yahoo.com · Dec 2024

Frequently asked questions

What does Telomir Pharmaceuticals do?: Telomir Pharma develops Telomir-Zn, a first-in-class oral therapy that modulates intracellular metal homeostasis to affect iron-dependent epigenetic machinery and reactivate tumor-suppressor genes silenced in cancer. Its lead program targets advanced and metastatic triple-negative breast cancer (TNBC), with an FDA-cleared IND for the TELO-001 Phase 1/2 clinical trial.
How much funding has Telomir Pharmaceuticals raised?: Telomir Pharmaceuticals has disclosed $2M raised across 2 rounds.
Where is Telomir Pharmaceuticals headquartered?: Telomir Pharmaceuticals is headquartered in Tampa, US.